Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity

20 Oct 2020

Abstract excerpt

Most recombinant adeno-associated virus (AAV) capsids utilized in liver gene therapy have significant levels of pre-existing neutralizing antibodies in the human population. These neutralizing factors limit the patient pools eligible for receiving AAV-mediated therapies. AAV serotype 5 (AAV5) does not face the same barrier of humoral immunity as most AAV serotypes due to its low seroprevalence. However, AAV5 can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33426144
DOI: 10.1016/j.omtm.2020.10.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral SeroreactivityPMID 33426144Read ↗

Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodiesSemantic proximity Read ↗

Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.Semantic proximity Read ↗

Substitution of Hexon Hypervariable Region 5 of Adenovirus Serotype 5 Abrogates Blood Factor Binding and Limits Gene Transfer to LiverSemantic proximity Read ↗

Attenuation of Heparan Sulfate Proteoglycan Binding Enhances In Vivo Transduction of Human Primary Hepatocytes with AAV2Semantic proximity Read ↗

A single amino acid variant in the variable region I of AAV capsid confers liver detargetingSemantic proximity Read ↗

Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapySemantic proximity Read ↗

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 CapsidSemantic proximity Read ↗

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based ConstructsSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8Semantic proximity Read ↗

Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar SyndromeSemantic proximity Read ↗

Optimization of AAV vectors to target persistent viral reservoirsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.